Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

L Ek, E Gezelius, B Bergman, P O Bendahl, H Anderson, J Sundberg, M Wallberg, U Falkmer, S Verma, M Belting, Swedish Lung Cancer Study Group (SLUSG), L Ek, E Gezelius, B Bergman, P O Bendahl, H Anderson, J Sundberg, M Wallberg, U Falkmer, S Verma, M Belting, Swedish Lung Cancer Study Group (SLUSG)

Abstract

Background: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may improve survival specifically in small-cell lung cancer (SCLC) patients by preventing VTE and tumor progression; however, randomized trials with well-defined patient populations are needed to obtain conclusive data. The aim of RASTEN was to investigate the survival effect of LMWH enoxaparin in a homogenous population of SCLC patients.

Patients and methods: We carried out a randomized, multicenter, open-label trial to investigate the addition of enoxaparin at a supraprophylactic dose (1 mg/kg) to standard treatment in patients with newly diagnosed SCLC. The primary outcome was overall survival (OS), and secondary outcomes were progression-free survival (PFS), incidence of VTE and hemorrhagic events.

Results: In RASTEN, 390 patients were randomized over an 8-year period (2008-2016), of whom 186 and 191 were included in the final analysis in the LMWH and control arm, respectively. We found no evidence of a difference in OS or PFS by the addition of enoxaparin [hazard ratio (HR), 1.11; 95% confidence interval (CI) 0.89-1.38; P = 0.36 and HR, 1.18; 95% CI 0.95-1.46; P = 0.14, respectively]. Subgroup analysis of patients with limited and extensive disease did not show reduced mortality by enoxaparin. The incidence of VTE was significantly reduced in the LMWH arm (HR, 0.31; 95% CI 0.11-0.84; P = 0.02). Hemorrhagic events were more frequent in the LMWH-treated group but fatal bleedings occurred in both arms.

Conclusion: LMWH enoxaparin in addition to standard therapy did not improve OS in SCLC patients despite being administered at a supraprophylactic dose and despite resulting in a significant reduction in VTE incidence. Addition of LMWH cannot be generally recommended in the management of SCLC patients, and predictive biomarkers of VTE and LMWH-associated bleeding in cancer patients are warranted.

Trial registration: ClinicalTrials.gov NCT00717938.

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Figures

Figure 1.
Figure 1.
CONSORT diagram of the RASTEN study population.
Figure 2.
Figure 2.
Kaplan–Meier curve of overall survival by treatment arm.
Figure 3.
Figure 3.
Kaplan–Meier curves of overall survival by disease extent according to treatment arm.
Figure 4.
Figure 4.
Cumulative incidence of first venous thromboembolism (VTE).

References

    1. Ervik M, Lam F, Ferlay J. et al. Cancer Today: Cancer fact sheets: Lung Cancer, 05/2016 update; .
    1. Walters S, Maringe C, Coleman MP. et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013; 68(6): 551–564.
    1. Blom JW, Doggen CJ, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293(6): 715–722.
    1. Rak J, Yu JL, Luyendyk J. et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66(22): 10643–10646.
    1. Kasthuri RS, Taubman MB, Mackman N.. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834–4838.
    1. Falanga A, Schieppati F, Russo D.. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin Thromb Hemost 2015; 41(07): 756–764.
    1. Petitou M, Casu B, Lindahl U.. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003; 85: 83–89.
    1. Niers TM, Klerk CP, DiNisio M. et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61(3): 195–207.
    1. Bendas G, Borsig L.. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J Cell Biol 2012; 2012: 676731.
    1. Belting M. Glycosaminoglycans in cancer treatment. Thromb Res 2014; 133: S95–S101.
    1. Noble S. Heparins and cancer survival: where do we stand? Thromb Res 2014; 133: S133–S138.
    1. Gould MK, Dembitzer AD, Doyle RL. et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130(10): 800–809.
    1. Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23(10): 2123–2129.
    1. Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22(10): 1944–1948.
    1. Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin. Oncol 2005; 23: 2130–2135.
    1. Altinbas M, Coskun HS, Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2(8): 1266–1271.
    1. Lebeau B, Chastang C, Brechot JM. et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994; 74(1): 38–45.
    1. Akl EA, Gunukula S, Barba M. et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011; 19: CD006652.
    1. Zhang J, Zhang YL, Ma KX. et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 2013; 68(5): 442–450.
    1. Macbeth F, Noble S, Evans J. et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC Trial. J Clin Oncol 2016; 34(5): 488–494.
    1. Stevenson JL, Choi SH, Varki A.. Differential metastasis inhibition by clinically relevant levels of heparins–correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11(19 Pt 1): 7003–7011.
    1. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 08/2006 update; (17 July 2015, date last accessed).
    1. Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics 2011; 67(1): 39–49.
    1. Fuster MM, Esko JD.. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5(7): 526–542.
    1. Key NS, Khorana AA, Mackman N. et al. Thrombosis in cancer: research priorities identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res 2016; 76(13): 3671–3675.
    1. Travis WD, Brambilla E, Nicholson AG. et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10(9): 1243–1260.
    1. Koizume S, Jin MS, Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66(19): 9453–9460.
    1. Wojtukiewicz MZ, Hempel D, Sierko E. et al. Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Rev 2015; 34(4): 775–796.
    1. Ori A, Wilkinson MC, Fernig DG.. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 2011; 286(22): 19892–19904.
    1. Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial. J Clin Oncol 2015; 33(18): 2028–2034.
    1. Slotman BJ, van Tinteren H, Praag JO. et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385(9962): 36–42.
    1. Mandalà M, Falanga A, Roila F.. ESMO Guidelines Working Group. Ann Oncol 2011; 22(Suppl 6): 85–92.
    1. Angelini D, Khorana AA.. Risk assessment scores for cancer-associated venous thromboembolic disease. Semin Thromb Hemost 2017; 43(05): 469–478.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅